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Abstract
Aims/hypothesis Hypoglycaemia is a common side effect of insulin and some other antihyperglycaemic agents used to treat
diabetes. Severe hypoglycaemia has been associated with adverse cardiovascular events in trials of intensive glycaemic control in
type 2 diabetes. The relationship between non-severe hypoglycaemic episodes (NSHEs) and severe hypoglycaemia in type 2
diabetes has been documented. However, an association between more frequent NSHEs and cardiovascular events has not been
verified. This post hoc analysis of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results) trial aimed to confirm whether there is an association between NSHEs and severe hypoglycaemic episodes
in individuals with type 2 diabetes. In addition, the possible association between NSHEs and major adverse cardiac events
(MACE), cardiovascular death and all-cause mortality was investigated.
Methods LEADER was a double-blind, multicentre, placebo-controlled trial that found that liraglutide significantly reduced the
risk ofMACE comparedwith the placebo. In this post hoc analysis, we explored, in all LEADER participants, whether the annual
rate of NSHEs (defined as self-measured plasma glucose <3.1 mmol/l [56 mg/dl]) was associated with time to first severe
hypoglycaemic episode (defined as an episode requiring the assistance of another person), time to first MACE, time to cardio-
vascular death and time to all-cause mortality. Participants with <2 NSHEs per year were used as reference for HR estimates. Cox
regression with a time-varying covariate was used.
Results We demonstrate that there is an association between NSHEs (2–11 NSHEs per year and ≥12 NSHEs per year) and severe
hypoglycaemic episodes (unadjusted HRs 1.98 [95% CI 1.43, 2.75] and 5.01 [95% CI 2.84, 8.84], respectively), which was consistent
when baseline characteristics were accounted for. Additionally, while no association was found between participants with 2–11 NSHEs
per year and adverse cardiovascular outcomes, higher rates ofNSHEs (≥12 episodes per year) were associatedwith higher risk ofMACE
(HR 1.50 [95% CI 1.01, 2.23]), cardiovascular death (HR 2.08 [95% CI 1.17, 3.70]) and overall death (HR 1.80 [95% CI 1.11, 2.92]).
Conclusions/interpretation The analysis of data from the LEADER trial demonstrated that higher rates of NSHEs were associ-
ated with both a higher risk of severe hypoglycaemia and adverse cardiovascular outcomes in individuals with type 2 diabetes.
Therefore, irrespective of the cause of this association, it is important that individuals with high rates of hypoglycaemia are
identified so that the potentially increased risk of cardiovascular events can be managed and steps can be taken to reduce NSHEs.
Trial registration ClinicalTrials.gov (NCT01179048).
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Abbreviations
ACCORD Action to Control Cardiovascular
Risk in Diabetes
LEADER Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results
MACE Major adverse cardiovascular event
NSHE Non-severe hypoglycaemic episode
ORIGIN Outcome Reduction With Initial
Glargine Intervention
SMPG Self-measured plasma glucose
Introduction
There is considerable evidence that individuals with type 1
and type 2 diabetes benefit greatly from maintaining good
glycaemic control [1, 2]; however, many do not reach their
treatment targets [3]. Unwanted treatment-associated side
effects, such as hypoglycaemia, are a barrier to optimal
glycaemic control in individuals with diabetes [4].
Hypoglycaemia is a common, potentially dangerous, side
effect of diabetes therapy, particularly with insulins and sulfo-
nylureas [5, 6], that may lead to confusion, coma and seizures
[7, 8]; and, unsurprisingly, fear of future episodes affects both
individuals and family members [9].
Analyses ofmajor clinical trials have investigated the relation-
ship between severe hypoglycaemia (defined as cognitive
impairment requiring assistance from another person) and
adverse cardiovascular outcomes. These analyses demonstrated
that severe hypoglycaemia was associated with an increased risk
of all-cause mortality and/or adverse cardiovascular outcomes in
individuals with type 2 diabetes [10–15]. In contrast, in
ACCORD (Action to Control Cardiovascular Risk in
Diabetes), while an increased risk of death was seen in all partic-
ipants experiencing symptomatic and severe hypoglycaemia, the
risk of death was lower in those experiencing one or more
hypoglycaemic episodes receiving intensive glucose control vs
standard glucose control [11, 12]. This suggests that factors other
than severe hypoglycaemia account for the mortality difference
between the two arms. Susceptibility to severe hypoglycaemia
couldmerely be amarker for an underlying disease that increases
the mortality risk for these individuals. Alternatively, the reduced
risk of mortality observed in patients treated intensively and
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experiencing hypoglycaemia may be due to repeated episodes of
hypoglycaemia leading to impaired sympathoadrenal responses,
which are linked to adverse cardiovascular effects [16].
Importantly, while an association between severe
hypoglycaemia and an increased risk of adverse cardiovascu-
lar events has been demonstrated, there is also evidence that
previous cardiovascular events are associated with severe
hypoglycaemia [17, 18]. However, recent evidence has shown
that the risk of cardiovascular events appears to increase with
an increasing hypoglycaemia risk score, supporting the
hypothesis that hypoglycaemia could be a risk factor for
adverse cardiovascular outcomes [19]. The bi-directional rela-
tionship between severe hypoglycaemia and cardiovascular,
and other non-vascular, conditions may merely reflect
increased vulnerability to hypoglycaemia and these other
conditions [13, 17]. If severe hypoglycaemia identifies ‘sicker
individuals’ who are more likely to experience cardiovascular
events, then it could be considered a risk marker of CVD,
irrespective of whether a causal link exists.
Non-severe hypoglycaemic episodes (NSHEs) have been
associated with a higher risk of cardiovascular events,
hospitalisation and all-cause mortality in some studies of indi-
viduals with type 2 diabetes, and of critically ill individuals
with and without diabetes [20, 21]. However, other studies
have found no association of NSHEs with cardiovascular
outcomes observed in participants with dysglycaemia and at
high risk of cardiovascular events [22], or in those with type 2
diabetes when measuring cardiovascular deaths over 4 years
[23].
Higher rates of NSHEs have been shown to be associated
with a greater risk of severe hypoglycaemia in individuals with
type 1 diabetes [24, 25], but the association in those with type 2
diabetes is unclear [22, 26, 27]. Some studies have reported an
association [26, 27], but others, including theORIGIN (Outcome
Reduction With Initial Glargine Intervention) trial, found no
association following adjustment for confounding variables
[22]. The link betweenNSHEs and severe hypoglycaemia is well
recognised, but the association of more frequent NSHEs with
cardiovascular events remains unresolved. To explore this rela-
tionship further, we examined the frequencies of non-severe and
severe hypoglycaemic events in a large population of patients
with type 2 diabetes and an increased cardiovascular risk.
LEADER (Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results) was a cardio-
vascular outcomes trial with a median follow-up of 3.8 years
comparing liraglutide with placebo in addition to standard of
care in individuals with type 2 diabetes and high cardiovascu-
lar risk [28]. The size and design of the LEADER trial, and the
relatively large number of NSHEs (defined as an event with
symptoms consistent with hypoglycaemia confirmed by a
concomitant glucose reading <3.1 mmol/l [56 mg/dl]), there-
fore provide an opportunity to investigate the association
between NSHEs and severe hypoglycaemic episodes in
individuals with type 2 diabetes. This analysis also aims to
investigate the possible associations between NSHEs and
major adverse cardiac events (MACE), cardiovascular death
and all-cause mortality, but does not aim to determine
causality.
Methods
Study design and participants The post hoc analyses described
below utilised data from the LEADER trial (NCT01179048).
Detailed descriptions of the protocol, methods and primary
results have been published previously [28, 29]. In brief,
LEADER was a double-blind, multicentre, placebo-controlled
trial that included 9340 participants with uncontrolled type 2
diabetes (HbA1c ≥ 53 mmol/mol [7%]) either ≥50 years old with
pre-existing CVD (81%), or ≥60 years old with at least one
cardiovascular risk factor (19%), as determined by the investiga-
tor. Participants were randomised 1:1 to receive either 1.8 mg (or
themaximum tolerated dose) of liraglutide or amatching placebo
once daily in addition to standard of care. Those that did notmeet
their target for glycaemic control (HbA1c ≤ 53mmol/mol [7%] or
an individualised target) after randomisation could receive addi-
tional antihyperglycaemic agents (excluding glucagon-like
peptide-1 [GLP-1] receptor agonists, dipeptidyl peptidase-4
[DPP-4] inhibitors or pramlintide) to their treatment.
Participants measured and recorded plasma glucose during
the trial using a single type of protocol-defined blood glucose
meter supplied by the study sponsor, along with instructions
for self-measurement of fasting glucose, at local investigators’
discretion. Glycaemic management was guided by review of
self-measured plasma glucose (SMPG) values and HbA1c
levels for the individual participants.
Participants provided written consent, which was approved
according to local regulations by appropriate health authori-
ties, and by an independent ethics committee/institutional
review board. The trial was conducted in accordance with
the Declaration of Helsinki, ICH Good Clinical Practice and
FDA 21 CFR 312.120 in the USA.
Outcomes In this post hoc analysis, we explored the possibil-
ity of annual rate of NSHEs being associated with time to first
severe hypoglycaemic episode, time to first MACE, time to
cardiovascular death and time to all-cause mortality. An
NSHE was defined as SMPG <3.1 mmol/l (56 mg/dl), and
severe hypoglycaemia defined as an episode requiring assis-
tance of another person to actively administer carbohydrate or
glucagon, or to take other corrective action [6]. MACE was a
composite of cardiovascular death, non-fatal myocardial
infarction and non-fatal stroke (three-point MACE), all of
which were adjudicated in an independent and blinded
manner by external event-adjudication committees. During
the total trial period of 35,563 patient years of observation
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(median follow-up of 3.8 years), 27,933 NSHEs were regis-
tered. There were 433 severe hypoglycaemic episodes, 1302
first cases of three-point MACE, 497 cases of cardiovascular
death and 828 cases of all-cause mortality [28].
Statistical analyses Data were analysed using a Cox propor-
tional hazards model and the annual rate of NSHEs was
modelled in a similar way to a previous study [26], as a
time-dependent covariate with three levels: Group A: <2
NSHEs per year (reference group); Group B: 2–11 NSHEs
per year; Group C: ≥12NSHEs per year. All analyses consider
time to first event.
The reference group comprised individuals with non-
frequent, non-severe hypoglycaemia (defined as <2 episodes
per year), and those with no reported NSHEs, based on the
assumption that these two groups of patients could be
combined.
Associations between annualised NSHEs and time to first
event were analysed using Cox proportional hazards regression
with minor hypoglycaemia rate. Minor hypoglycaemia refers to
any NSHE (symptomatic or asymptomatic) with an SMPG
measurement <3.1mmol/l (56mg/dl) as a time-dependent covar-
iate and using a fixed-window approach where follow-up time
was divided into 100-day windows [30, 31]. Analyses were
made using an unadjusted model, and two models that adjusted
for baseline characteristics. The first adjusted model accounted
for age, sex, baseline HbA1c and diabetes duration (≥15 years,
yes/no). The second adjusted model accounted for renal function
in addition to the other characteristics described above, classify-
ing participants according to eGFR as normal (≥90ml/min), mild
impairment (<90–60 ml/min), moderate impairment (<60–
30 ml/min) or severe impairment (<30 ml/min). HRs and 95%
CIs for the associations of minor hypoglycaemia rate and time to
first event were reported.
Three major sensitivity analyses were performed. The first
was similar to the main analysis, except that the time-
dependent covariate was updated each time a new severe
hypoglycaemia event, MACE, cardiovascular death or overall
death occurred, depending on the specific analysis, and was
not baseline-adjusted. In the second sensitivity analysis, the
first year of follow-up was used to classify participants
according to their minor hypoglycaemia rate, and time to first
event in the analysis was based on the remaining follow-up
time (>1 year). Individuals with less than 1 year of follow-up
were excluded from this analysis. Finally, in a third sensitivity
analysis on MACE and cardiovascular death, all participants
who had one or more severe hypoglycaemic episodes during
follow-up were excluded from the analysis.
Finally, the data were analysed adjusted for insulin use
(baseline or during trial, yes/no), and then analysed using a
more stringent NSHE reference category of zero NSHE
events: Group A: no NSHEs; Group B: >0 to <12 NSHEs;
Group C: ≥12 NSHEs.
Results
Baseline characteristics Table 1 shows the baseline character-
istics of participants categorised according to their highest
observed annual NSHE rate (Groups A–C). Baseline charac-
teristics were similar for age, BMI and sex distribution.
Participants in Group C (≥12 NSHEs per year) had a longer
duration of diabetes and were less likely to be insulin naive.
Relationship between NSHEs and severe hypoglycaemia For
the three categories of NSHE rate, Group A (<2 NSHEs per
year), Group B (2–11 NSHEs per year) and Group C (≥12
NSHEs per year), the numbers of severe hypoglycaemic
episodes were 208, 46 and 13, respectively.
The main analysis showed that participants in both Group
B and Group C experienced higher rates of severe
hypoglycaemia compared with Group A (unadjusted HR
1.98 [95% CI 1.43, 2.75] and 5.01 [95% CI 2.84, 8.84],
respectively; Fig. 1a). Results were similar when the main
analysis was adjusted for baseline characteristics including
renal function (Fig. 1b,c).
In the first sensitivity analysis, where the time-dependent
covariate was updated at each NSHE time, the HR for severe
hypoglycaemia in Group C vs Group A was smaller compared
with the main analysis, but the 95% CI was narrower (HR 3.11
[95%CI 2.18, 4.44]; Fig. 2a). TheHR forGroupB vsGroupA in
this sensitivity analysis was marginally higher than that observed
in the main analysis (HR 2.31 [95% CI 1.74, 3.07]; Fig. 2a).
The second sensitivity analysis, which categorised partici-
pants by NSHE annual event rate in the first 12 months, was
similar to the main analysis (HR 1.83 [95% CI 1.32, 2.55] and
HR 4.93 [95% CI 2.84, 8.56]; Fig. 2b) for Group B vs A and
Group C vs A, respectively.
When the data were adjusted for insulin use (baseline or
during trial, yes/no), although point estimates were slightly atten-
uated, overall results were similar to the main analysis. HRs
[95% CI] for Groups B and C, vs A, for severe hypoglycaemia
were 1.72 [1.24, 2.39] and 4.09 [2.31, 7.22], respectively.
A repeat of the main analysis using a more stringent NSHE
reference category (Group A: no NSHEs; Group B: >0 to <12
NSHEs; Group C: ≥12 NSHEs) did not change the results
substantially. The unadjusted HRs for severe hypoglycaemia
for Groups B and C vs Group A were 2.22 [95% CI 1.69,
2.92] and 5.95 [95% CI 3.34, 10.62], respectively.
Relationship between NSHEs and cardiovascular outcomes
For the three categories of NSHE rate, Group A (<2 NSHEs
per year), Group B (2–11 NSHEs per year) and Group C (≥12
NSHEs per year), the numbers of cardiovascular events were:
& MACE: 1128, 149 and 25, respectively
& Cardiovascular death: 422, 63 and 12, respectively
& Overall death: 711, 100 and 17, respectively.
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The main analysis found that the HRs for adverse cardiovas-
cular outcomes was similar between Groups A and B (Fig. 1).
However, the higher rate of NSHEs in Group C was associated
with a higher rate of MACE (HR 1.50 [95% CI 1.01, 2.23]),
cardiovascular death (HR 2.08 [95% CI 1.17, 3.70]) and all-
cause mortality (HR 1.80 [95% CI 1.11, 2.92]) in the main anal-
ysis (Fig. 1a). When baseline characteristics were accounted for
(excluding renal function), the rates of MACE, cardiovascular
death and all-cause mortality were consistent with the unadjusted
analysis (Fig. 1b). The analysis that accounted for baseline char-
acteristics, including renal function, showed a smaller HR
between NSHE Groups C and A for MACE (HR 1.42 [95%
CI 0.95, 2.12]), cardiovascular death (HR 1.77 [95% CI 0.99,
3.16]) and all-cause mortality (HR 1.56 [95% CI 0.96, 2.53];
Fig. 1c) compared with the unadjusted analysis.
The first sensitivity analysis (Fig. 2a) was consistent with the
main analysis in demonstrating an increased risk of MACE,
cardiovascular death and all-cause mortality in NSHE Group
C vs Group A. The first sensitivity analysis had narrower CIs
than the main analysis, suggesting an association between
previous NSHE and MACE (HR 1.32 [95% CI 1.07, 1.63]),
cardiovascular death (HR 1.53 [95% CI 1.11, 2.11]) and all-
cause mortality (HR 1.56 [95% CI 1.21, 2.00]).
In the second sensitivity analysis, which categorised partici-
pants byNSHE event rate in the first 12months and only consid-
ered follow-up after the first year, the total number of events was
notably reduced compared with the main analysis (Fig. 2b).
Compared with the main analysis, this sensitivity analysis result-
ed in smaller HRs between Group C and Group A for MACE
(HR 1.24 [95% CI 0.81, 1.89]), cardiovascular death (HR 1.57
[95% CI 0.88, 2.78]) and all-cause mortality (HR 1.35 [95% CI
0.83, 2.19]).
In the third sensitivity analysis, when we excluded partic-
ipants who experienced one or more severe hypoglycaemic
episodes during follow-up, the association between NSHEs
and cardiovascular death or overall death in Group C (HR
2.00 [95% CI 1.10, 3.65]; HR 1.68 [95% CI 1.00, 2.80],
respectively) remained similar to the main analysis.
However, the HR between NSHE Groups C and A for
MACE was smaller (HR 1.25 [95% CI 0.80, 1.94]; Fig. 2c)
than that seen in the main analysis.
When the data were adjusted for insulin use (baseline or
during trial, yes/no), although point estimates were slightly
attenuated, overall results were similar to the main analysis.
HRs [95% CI] for Group B and C, vs A, for MACE were 0.98
[0.83, 1.17] and 1.42 [0.95, 2.12]; for cardiovascular death
were 1.13 [0.87, 1.48] and 2.04 [1.15, 3.64]; and for overall
death were 1.05 [0.85, 1.30] and 1.72 [1.06, 2.79].
A repeat of the main analysis using a more stringent NSHE
reference category (Group A: no NSHEs; Group B: >0 to <12
NSHEs; Group C: ≥12 NSHEs) did not change the results
substantially. The HRs for MACE for Groups B and C vs
Group A were 0.99 [95% CI 0.88, 1.12] and 1.49 [95% CI
1.00, 2.22], respectively. The HRs for cardiovascular death for
Groups B and C vs Group A were 0.90 [95% CI 0.74, 1.09]
and 1.97 [95% CI 1.11, 3.51], respectively. The HRs for over-
all death for Groups B and C vs Group A were 1.04 [95% CI
0.90, 1.20] and 1.81 [95% CI 1.11, 2.94], respectively.
Discussion
This post hoc analysis of the LEADER data identified an
association between NSHEs and severe hypoglycaemic
episodes. Importantly, the study showed that a high rate of
NSHEs (≥12NSHEs per year) was also associatedwith higher
rates of adverse cardiovascular outcomes, including MACE,




(<2 NSHEs per year)
(n=7019)
Group B
(2–11 NSHEs per year)
(n=1919)
Group C
(≥12 NSHEs per year)
(n=395)
Age (years) 64.3 (7.2) 64.2 (7.3) 64.6 (7.1) 64.2 (6.9)
Female (%) 35.7 35.3 36.1 40.8
BMI (kg/m2) 32.5 (6.3) 32.8 (6.4) 31.8 (6.0) 31.2 (6.2)
HbA1c (mmol/mol) 71.5 (16.7) 71.8 (17.0) 70.8 (15.8) 70.1 (15.5)
HbA1c (%) 8.7 (1.5) 8.7 (1.6) 8.6 (1.4) 8.6 (1.4)
Diabetes duration (years) 12.8 (8.0) 12.0 (7.7) 14.8 (8.2) 17.4 (8.8)
Insulin naive (%) 55.4 60.3 42.5 30.9
eGFR (ml min−1 [1.73 m]−2) 81.5 (27.7) 83.3 (27.6) 76.7 (27.0) 72.93 (26.6)
Chronic kidney failure (%)a 24.7 22.5 30.4 36.5
Existing CVD (%) 81.3 80.7 82.7 85.3
Systolic BP (mmHg) 135.9 (17.7) 136.1 (17.6) 134.9 (17.8) 136.5 (19.8)
Diastolic BP (mmHg) 77.1 (10.2) 77.5 (10.1) 75.9 (10.6) 75.8 (10.3)
Data are mean (SD) or %
Participants were grouped according to their highest annual NSHE rate. Owing to incomplete baseline information, seven individuals were not included
a eGFR <60 ml min−1 [1.73 m]−2
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cardiovascular death and all-cause mortality, in individuals
with type 2 diabetes.
Our analysis confirms recent evidence associating NSHEs
with increased risk of severe hypoglycaemia [26, 27]. Festa
et al. conducted an analysis of patients with type 2 diabetes
initiating insulin, investigating the relationship between
NSHEs and severe hypoglycaemia using a clinical trial data-
base (N = 2931 from three trials) [26]. They found that the risk
of severe hypoglycaemia was higher for participants
experiencing multiple NSHEs compared with those
experiencing ≤1 NSHEs per month (HR 4.24 [95% CI 2.57,
6.99] p < 0.0001) [26]; our analysis results are consistent with
these data. Roussel et al. [27] conducted a systematic analysis
of published data for insulin-treated patients, and found that
the incidence of NSHEs, especially nocturnal NSHEs, were
the best predictor of severe hypoglycaemic events.
Fig. 1 Time-dependent covariate
analysis of a Cox proportional
hazards model for severe
hypoglycaemia, MACE,
cardiovascular death and all-
cause mortality by NSHE rate
groups: (a) unadjusted; (b)
adjusted for baseline
characteristics (excluding renal
function); (c) adjusted for
baseline characteristics (including
renal function). Reference group,
Group A: <2 NSHEs per year;
Group B: 2–11 NSHEs per year;
Group C: ≥12 NSHEs per year
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We also found an association between the higher rate of
NSHEs (≥12 NSHEs per year) and adverse cardiovascular
outcomes, consistent with multiple sensitivity analyses.
There is considerable evidence demonstrating an association
between hypoglycaemia and the development of cardiovascu-
lar complications in type 2 diabetes [32–34], including
secondary analyses of a number of large diabetes trials such
as ADVANCE (Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation) [13] and
LEADER [12]. It is worth noting that this association was not
seen in the ORIGIN trial, perhaps because the NSHEs patient
group in ORIGIN experienced a median of 0.34 NSHEs over
a median of 6.2 years, compared with ≥12 NSHEs per year in
Group C of this study [22]. However, parallels can be drawn
between LEADER and ORIGIN [22]. While NSHEs were not
associated with cardiovascular outcomes after adjustment in
ORIGIN, in LEADER, no association was found between the
rate of NSHEs and adverse cardiovascular outcomes in Group
C when accounting for baseline characteristics, including
renal function, or in Group B (2–11 NSHEs per year). Both
studies found severe hypoglycaemia associated with a higher
risk for cardiovascular outcomes.
Fig. 2 Sensitivity analyses for the
association of NSHE and other
events. (a) Time-dependent
covariate sensitivity analysis of
NSHEs and outcomes, where
exposure time was split when a
new outcome event occurred. (b)
The first year of exposure was
used to group participants in one
of three risk categories, and the
remainder of the exposure time
was used to study the association
between risk category and time to
first event. (c) Same as main
analysis but severe
hypoglycaemia events were
excluded from the dataset.
Reference group, Group A: <2
NSHEs per year; Group B: 2–11
NSHEs per year; Group C: ≥12
NSHEs per year
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Participants enrolled in the LEADER study who experienced
severe hypoglycaemic episodes were more likely to experience
MACE, cardiovascular death and all-cause mortality compared
with those with no experience of severe hypoglycaemia. The risk
of adverse cardiovascular events was particularly high in the
immediate period following episodes of severe hypoglycaemic
events [12]. As these findings are based on a post hoc analysis of
LEADER, it remains uncertain if hypoglycaemia is a marker or
mediator of associated cardiovascular risk. A bi-directional asso-
ciation between severe hypoglycaemia and cardiovascular
events, with greater risk of cardiovascular events after severe
hypoglycaemia and vice versa, particularly in individuals with
comorbidities, is evident [18]. The presence of comorbidities
does not, however, fully explain this association [35]. Evidence
from the DEVOTE trial also supports an association between
severe hypoglycaemia and MACE. While this analysis cannot
be considered conclusive evidence of a causal link, the results
imply that individuals with high rates of MACE are also those
with high rates of hypoglycaemia. In the absence of an RCT to
assess this relationship, which is neither possible nor ethical,
evidence supports the hypothesis that hypoglycaemia is both a
risk marker and risk factor for cardiovascular events [19].
Furthermore, independent of causality, reducing the risk of any
hypoglycaemia by lifestyle intervention or pharmacological solu-
tions will benefit individuals using insulin, including those at
high cardiovascular risk.
Interestingly, when participants experiencing one or more
severe hypoglycaemic episodes were excluded from the analysis,
the association between NSHEs and MACE was reduced in
those experiencing ≥12 NSHEs per year; however, the relation-
ships between NSHEs and cardiovascular death, or NSHEs and
overall death, remained consistent with the main analysis. This
indicates that the association between NSHEs and MACE is at
least partly driven by those individuals who have a high rate of
NSHEs and who also have severe hypoglycaemic events. Yet
even when all participants who have experienced an episode of
severe hypoglycaemia have been removed from the dataset there
is still an association between NSHEs and cardiovascular death.
There are a number of pathways involved in the response to
hypoglycaemia that may be causally linked to adverse cardiovas-
cular outcomes, particularly if non-severe events are experienced
repeatedly over a period of weeks or months. Experimentally
induced moderate hypoglycaemia (defined as 2.5 mmol/l
[45 mg/dl]) is associated with acute and persistent prothrombotic
effects, illustrating a possible mechanism by which
hypoglycaemia might increase cardiovascular risk [36].
Hypoglycaemia also provokes an increase in plasma aldosterone,
and this may exacerbate vascular dysfunction through the activa-
tion of the mineralocorticoid receptor [37]. A proinflammatory
response characterised by platelet and monocyte activation is
initiated during experimentally induced acute moderate
hypoglycaemia (blood glucose of approximately 2.5 mmol/l
[45 mg/dl]), which could also play a role in the adverse
cardiovascular outcomes reported [32, 38, 39]. Finally, in indi-
viduals with type 2 diabetes and at high cardiovascular risk,
hypoglycaemia has also been associated with increased risk of
cardiac arrhythmias, possibly via perturbations in cardiac auto-
nomic tone and abnormal repolarisation [40, 41].
In LEADER, over 80% of people had prior CVD at
randomisation. The current findings therefore mainly apply
to a secondary prevention population, who are at high risk
of recurrent cardiovascular events.
The association between NSHEs and adverse cardiovascular
outcomes was attenuated when our analysis accounted for base-
line renal function. This could be due to shared vulnerabilities in
people with chronic kidney disease for hypoglycaemia and
adverse cardiovascular events. A similar association has been
shown in a subanalysis of DEVOTE, which found that after
adjustment, participants with a baseline eGFR of 60–
<90 ml min−1 [1.73 m]−2 no longer had significantly higher risks
of cardiovascular death and all-cause mortality compared with
those with baseline eGFR ≥90 ml min−1 [1.73 m]−2, in addition
to a non-significant increased risk of severe hypoglycaemia [42].
Aside from an association between severe hypoglycaemia and
cardiovascular outcomes, in the context of hypoglycaemia, an
aspect of interest is ‘frailty’ [43]. Chronic inflammation and insu-
lin resistance may increase frailty incidence, while a frail status
may also cause these conditions, which in turnmay be associated
with CVD [43]. Frailty has been found to be an independent risk
factor for CVD [44], and a significant relationship has been
demonstrated between frailty and CVD [45]. Further,
hypoglycaemia in older people is associated with significant
morbidity, and recurrent hypoglycaemia is associated with dete-
rioration in general health, which is likely to lead to frailty and
poor outcomes [46]. This relationship between hypoglycaemia
and frailty appears to be bi-directional, mediated through factors
such as undernutrition and reduced muscle mass [46]. Thus, it
could be argued that severe hypoglycaemia and cardiovascular
outcomes are markers of a frail state in which the patient is more
likely to have both severe hypoglycaemia and CVD, as well as
other conditions, including non-cardiovascular death.
The main limitation of the study is that it was a post hoc
hypothesis-generating analysis, rather than a primary analysis
with a specific endpoint to investigate the relationship between
NSHEs, severe hypoglycaemia and adverse cardiovascular
outcomes. We were also unable to conduct an analysis adjusting
for the duration of insulin as this information was not available
for LEADER. Additionally, SMPG measurements were not
embedded into the LEADER protocol, and were likely to be
more common in those with prior glucose variability, previous
experience of hypoglycaemia and those on insulin therapy.
However, the large size of the population studied, the relatively
high number of NSHEs available for the analysis, and the consid-
erable length of follow-up provides a strong basis for the
evidence of an association of NSHEswith severe hypoglycaemia
and adverse cardiovascular outcomes.
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In conclusion, the data from LEADER, a long-term cardio-
vascular outcomes trial, demonstrated that higher rates of
NSHEs were associated with higher rates of severe
hypoglycaemia, MACE, cardiovascular death and all-cause
mortality in individuals with type 2 diabetes. We would argue
strongly that, whatever the underlying driver of the link
between CVD and hypoglycaemia, it is important that
healthcare professionals and patients take steps to reduce this
common complication of treatment.
Acknowledgements The authors thank all those who participated in the
original LEADER trial. Medical writing support for the development of
this manuscript, under the direction of the authors, was provided by K.
Guest, J. Sawyers and C. Lowe of Ashfield MedComms, an Ashfield
Health company, and funded by Novo Nordisk. Parts of this study were
presented as a poster presentation at the ADA 79th Annual Scientific
Sessions, 7–11 June 2019, San Francisco, California, USA.
Data availability The patient-level analysis datasets for the research
presented in the publication are available from the corresponding author
on reasonable request.
Funding This study was sponsored by Novo Nordisk. Medical writing
and editing assistance were also provided by Novo Nordisk. Novo
Nordisk was involved in the trial design and protocol development,
provided logistical support and obtained the data for this post hoc
analysis.
Authors’ relationships and activities SH has served on speaker panels
forMSD, Eli Lilly, Takeda, NovoNordisk and AstraZeneca, for which he
has received remuneration. He has served on advisory panels or as a
consultant for Zealand, UNEEG Medical, Boehringer Ingelheim, Novo
Nordisk, Eli Lilly and Takeda, for which his institution has received
remuneration. LW, MSG and LL are employees of Novo Nordisk and
LL owns shares in the company. AI declares that there are no relation-
ships or activities that might bias, or be perceived to bias, his work.
Contribution statement All authors confirm that they have contributed
to: collection of data, critical analysis and interpretation of the data,
drafting/critically revising the article, sharing in the final responsibility
for the content of the manuscript and the decision to submit it for publi-
cation and have approved the final version. They therefore meet the
International Committee of Medical Journal Editors (ICMJE) uniform
requirements for authorship. SH is the guarantor of this work and, as
such, had full access to all data in the study and takes responsibility for
the integrity of the data.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Holman RR, Paul SK, Bethel MA,Matthews DR, Neil HA (2008) 10-
year follow-up of intensive glucose control in type 2 diabetes. N Engl J
Med 359(15):1577–1589. https://doi.org/10.1056/NEJMoa0806470
2. Nathan DM (2014) The diabetes control and complications trial/
epidemiology of diabetes interventions and complications study at
30 years: overview. Diabetes Care 37(1):9. https://doi.org/10.2337/
dc13-2112
3. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G,
Gregg EW (2013) Achievement of goals in U.S. diabetes care,
1999-2010. N Engl J Med 368(17):1613–1624. https://doi.org/10.
1056/NEJMsa1213829
4. Fidler C, Elmelund Christensen T, Gillard S (2011) Hypoglycemia:
an overview of fear of hypoglycemia, quality-of-life, and impact on
costs. J Med Econ 14(5):646–655. https://doi.org/10.3111/
13696998.2011.610852
5. UK Hypoglycaemia Study Group (2007) Risk of hypoglycaemia in
types 1 and 2 diabetes: effects of treatment modalities and their
duration. Diabetologia 50(6):1140–1147. https://doi.org/10.1007/
s00125-007-0599-y
6. Seaquist ER, Anderson J, Childs B et al (2013) Hypoglycemia and
diabetes: a report of a workgroup of the American Diabetes
Association and the Endocrine Society. Diabetes Care 36(5):
1384–1395. https://doi.org/10.2337/dc12-2480
7. Arieff AI, Doerner T, Zelig H, Massry SG (1974) Mechanisms of
seizures and coma in hypoglycemia. Evidence for a direct effect of
insulin on electrolyte transport in brain. J Clin Invest 54(3):654–
663. https://doi.org/10.1172/jci107803
8. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ (2011)
Characterizing sudden death and dead-in-bed syndrome in type 1
diabetes: analysis from two childhood-onset type 1 diabetes regis-
tries. Diabet Med 28(3):293–300. https://doi.org/10.1111/j.1464-
5491.2010.03154.x
9. Frier BM (2008) How hypoglycaemia can affect the life of a person
with diabetes. Diabetes Metab Res Rev 24(2):87–92. https://doi.
org/10.1002/dmrr.796
10. Davis SN,DuckworthW, Emanuele N et al (2019) Effects of severe
hypoglycemia on cardiovascular outcomes and death in the
Veterans Affairs diabetes trial. Diabetes Care 42(1):157–163.
https://doi.org/10.2337/dc18-1144
11. Bonds DE, Miller ME, Bergenstal RM et al (2010) The association
between symptomatic, severe hypoglycaemia and mortality in type
2 diabetes: retrospective epidemiological analysis of the ACCORD
study. BMJ 340:b4909. https://doi.org/10.1136/bmj.b4909
12. Zinman B, Marso SP, Christiansen E et al (2018) Hypoglycemia,
cardiovascular outcomes, and death: the LEADER experience.
Diabetes Care 41(8):1783–1791. https://doi.org/10.2337/dc17-2677
13. Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia
and risks of vascular events and death. N Engl J Med 363(15):
1410–1418. https://doi.org/10.1056/NEJMoa1003795
14. Pieber TR, Marso SP, McGuire DK et al (2018) DEVOTE 3:
temporal relationships between severe hypoglycaemia, cardiovas-
cular outcomes and mortality. Diabetologia 61(1):58–65. https://
doi.org/10.1007/s00125-017-4422-0
15. Heller SR, Bergenstal RM, White WB et al (2017) Relationship of
glycated haemoglobin and reported hypoglycaemia to cardiovascu-
lar outcomes in patients with type 2 diabetes and recent acute coro-
nary syndrome events: the EXAMINE trial. Diabetes, Obes Metab
19(5):664–671. https://doi.org/10.1111/dom.12871
16. Ma Y, Wang Q, Joe D, Wang M, Whim MD (2018) Recurrent
hypoglycemia inhibits the counterregulatory response by suppress-
ing adrenal activity. J Clin Invest 128(9):3866–3871. https://doi.
org/10.1172/jci91921
Diabetologia
17. Standl E, Stevens SR, Armstrong PW et al (2018) Increased risk of
severe hypoglycemic events before and after cardiovascular outcomes
in TECOS suggests an at-risk type 2 diabetes frail patient phenotype.
Diabetes Care 41(3):596–603. https://doi.org/10.2337/dc17-1778
18. Standl E, Stevens SR, Lokhnygina Y et al (2019) Confirming the
bidirectional nature of the association between severe hypoglycemic
and cardiovascular events in type 2 diabetes: insights from EXSCEL.
Diabetes Care 43(3):643–652. https://doi.org/10.2337/dc19-1079
19. Heller S, Lingvay I, Marso SP et al (2020) Risk of severe
hypoglycaemia and its impact in type 2 diabetes in DEVOTE.
Diabetes, Obes Metab 22(12):2241–2247. https://doi.org/10.1111/
dom.14049
20. Hsu P-F, Sung S-H, Cheng H-M et al (2013) Association of clinical
symptomatic hypoglycemia with cardiovascular events and total
mortality in type 2 diabetes: a nationwide population-based study.
Diabetes Care 36(4):894–900. https://doi.org/10.2337/dc12-0916
21. Nice-Sugar Study Investigators, Finfer S, Liu B et al (2012)
Hypoglycemia and risk of death in critically ill patients. N Engl J
Med 367(12):1108–1118. https://doi.org/10.1056/NEJMoa1204942
22. ORIGIN Trial Investigators, Mellbin LG, Rydén L et al (2013)
Does hypoglycaemia increase the risk of cardiovascular events? A
report from the ORIGIN trial. Eur Heart J 34(40):3137–3144.
https://doi.org/10.1093/eurheartj/eht332
23. Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD
(2016) Relationship of glycaemic control and hypoglycaemic
episodes to 4-year cardiovascular outcomes in people with type 2
diabetes starting insulin. Diabetes, Obes Metab 18(2):152–158.
https://doi.org/10.1111/dom.12598
24. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D,
Schlundt D, Clarke W (1998) Assessment of risk for severe hypo-
glycemia among adults with IDDM: validation of the low blood
glucose index. Diabetes Care 21(11):1870–1875. https://doi.org/10.
2337/diacare.21.11.1870
25. Beck R, Bergenstal R, Riddlesworth T et al (2019) Validation of
time in range as an outcome measure for diabetes clinical trials.
Diabetes Care 3(42):400–405. https://doi.org/10.2337/dc18-1444
26. Festa A, Heller SR, Seaquist E, Duan R, Hadjiyianni I, Fu H (2017)
Association between mild and severe hypoglycemia in people with
type 2 diabetes initiating insulin. J Diabetes Complicat 31(6):1047–
1052. https://doi.org/10.1016/j.jdiacomp.2016.12.014
27. Roussel R, Moutairou A, Riveline J-P, Gautier J-F, Potier L (2019)
1091-P: association between mild and severe hypoglycemia in
people with T1 and T2 diabetes enrolled in randomized controlled
trials for assessing insulin therapy. Diabetes 68(Supplement 1):
1091. https://doi.org/10.2337/db19-1091-P
28. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide
and cardiovascular outcomes in type 2 diabetes. N Engl J Med
375(4):311–322. https://doi.org/10.1056/NEJMoa1603827
29. Marso SP, Poulter NR, Nissen SE et al (2013) Design of the
liraglutide effect and action in diabetes: evaluation of cardiovascu-
lar outcome results (LEADER) trial. Am Heart J 166(5):823–830.
https://doi.org/10.1016/j.ahj.2013.07.012
30. Fisher LD, Lin DY (1999) Time-dependent covariates in the Cox
proportional-hazards regression model. Annu Rev Public Health
20145–20157. https://doi.org/10.1146/annurev.publhealth.20.1.
145
31. Therneau T, Crowson C, Atkinson E (2019) Using time dependent
covariates and time dependent coefficients in the Cox model.
Available from https://cran.r-project.org/web/packages/survival/
vignettes/timedep.pdf
32. International Hypoglycaemia Study Group (2019) Hypoglycaemia,
cardiovascular disease, and mortality in diabetes: epidemiology,
pathogenesis, and management. Lancet Diabetes Endocrinol 7(5):
385–396. https://doi.org/10.1016/S2213-8587(18)30315-2
33. Bedenis R, Price AH, Robertson CM et al (2014) Association
between severe hypoglycemia, adverse macrovascular events, and
inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes
Care 37(12):3301–3308. https://doi.org/10.2337/dc14-0908
34. Yeh JS, Sung S-H, Huang H-M et al (2016) Hypoglycemia and risk
of vascular events and mortality: a systematic review and meta-
analysis. Acta Diabetol 53(3):377–392. https://doi.org/10.1007/
s00592-015-0803-3
35. Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe
hypoglycaemia and cardiovascular disease: systematic review and
meta-analysis with bias analysis. BMJ 347:f4533–f4533. https://
doi.org/10.1136/bmj.f4533
36. Chow E, Iqbal A, Walkinshaw E et al (2018) Prolonged
prothrombotic effects of antecedent hypoglycemia in individuals
with type 2 diabetes. Diabetes Care 41(12):2625–2633. https://doi.
org/10.2337/dc18-0050
37. Adler GK, Bonyhay I, Curren V, Waring E, Freeman R (2010)
Hypoglycaemia increases aldosterone in a dose-dependent fashion.
Diabet Med 27(11):1250–1255. https://doi.org/10.1111/j.1464-
5491.2010.03087.x
38. Ratter JM, Rooijackers HMM, Tack CJ et al (2017)
Proinflammatory effects of hypoglycemia in humans with or with-
out diabetes. Diabetes 66(4):1052–1061. https://doi.org/10.2337/
db16-1091
39. Iqbal A, Prince LR, Novodvorsky P et al (2018) Effect of hypogly-
cemia on inflammatory responses and the response to low-dose
endotoxemia in humans. J Clin Endocrinol Metab 104(4):1187–
1199. https://doi.org/10.1210/jc.2018-01168
40. Chow E, Bernjak A, Walkinshaw E et al (2017) Cardiac autonomic
regulation and repolarization during acute experimental hypoglyce-
mia in type 2 diabetes. Diabetes 66(5):1322–1333. https://doi.org/
10.2337/db16-1310
41. Chow E, Bernjak A, Williams S et al (2014) Risk of cardiac
arrhythmias during hypoglycemia in patients with type 2 diabetes
and cardiovascular risk. Diabetes 63(5):1738–1747. https://doi.org/
10.2337/db13-0468
42. Amod A, Buse JB, McGuire DK et al (2020) Glomerular filtration
rate and associated risks of cardiovascular events, mortality, and
severe hypoglycemia in patients with type 2 diabetes: secondary
analysis (DEVOTE 11). Diabetes Ther 11(1):53–70. https://doi.
org/10.1007/s13300-019-00715-x
43. Ida S, Kaneko R, Imataka K, Murata K (2019) Relationship
between frailty and mortality, hospitalization, and cardiovascular
diseases in diabetes: a systematic review and meta-analysis.
Cardiovasc Diabetol 18(1):81. https://doi.org/10.1186/s12933-
019-0885-2
44. Veronese N, Cereda E, Stubbs B et al (2017) Risk of cardiovascular
disease morbidity and mortality in frail and pre-frail older adults:
results from a meta-analysis and exploratory meta-regression anal-
ysis. Ageing Res Rev 35:63–73. https://doi.org/10.1016/j.arr.2017.
01.003
45. Chao CT, Wang J, Chien KL (2018) Both pre-frailty and frailty
increase healthcare utilization and adverse health outcomes in
patients with type 2 diabetes mellitus. Cardiovasc Diabetol 17(1):
130. https://doi.org/10.1186/s12933-018-0772-2
46. Abdelhafiz AH, Rodríguez-Mañas L, Morley JE, Sinclair AJ
(2015) Hypoglycemia in older people - a less well recognized risk
factor for frailty. Aging Dis 6(2):156–167. https://doi.org/10.
14336/ad.2014.0330
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Diabetologia
